Hydroxybenzophenone Compounds for Antiviral and Antitumor Therapy

The patent applies parameter changes by modifying the chemical structure of benzophenone compounds through specific hydroxyl substitutions (di-, tri-, tetra-, penta-, and hexahydroxy substitutions at various positions) to optimize the balance between anti-tumor effectiveness and toxicity. The structure-activity relationship studies identify that certain hydroxyl substitution patterns produce compounds with enhanced selective cytotoxicity against tumor cells while reducing harm to normal cells.

The patent employs local quality by introducing hydroxyl groups at specific positions on the benzophenone molecular structure (ortho, meta, para positions on both phenyl rings) to create localized functional regions that selectively interact with tumor cell targets. This localized modification allows the compound to exhibit selective toxicity toward tumor cells while maintaining lower toxicity to normal cells.

The patent applies universality by designing hydroxybenzophenone compounds that simultaneously exhibit multiple functions: they inhibit HIV-1 integrase activity, block herpes virus replication, and demonstrate anti-tumor effects. This multi-functionality reduces the likelihood of resistance development because the compounds affect multiple viral and cellular targets rather than a single enzyme active site.

The patent employs composite materials by combining the benzophenone core structure with multiple hydroxyl functional groups in specific configurations, creating a composite molecular architecture that can interact with multiple biological targets. The combination of the aromatic core with polyhydroxy substituents creates a multifaceted molecule capable of binding to integrase, viral proteins, and tumor cell targets through different interaction mechanisms.